Bone Metastasis - Pipeline Review, H2 2015

Description:

Bone Metastasis - Pipeline Review, H2 2015

Summary


This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bone Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bone Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction

REPORT COVERAGE

Bone Metastasis Overview

Therapeutics Development

Pipeline Products for Bone Metastasis - Overview
Pipeline Products for Bone Metastasis - Comparative Analysis
Bone Metastasis - Therapeutics under Development by Companies
Bone Metastasis - Therapeutics under Investigation by Universities/Institutes
Bone Metastasis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Bone Metastasis - Products under Development by Companies
Bone Metastasis - Products under Investigation by Universities/Institutes
Bone Metastasis - Companies Involved in Therapeutics Development

Ablynx NV
Aegera Therapeutics Inc.
Alethia Biotherapeutics Inc.
Amgen Inc.
Amura Holdings Limited
Bayer AG
ChemoCentryx, Inc.
Debiopharm International S.A.
Deciphera Pharmaceuticals, LLC
Digna Biotech, S.L.
Kyowa Hakko Kirin Co., Ltd.
Medivir AB
Merrion Pharmaceuticals Plc
Oncobiologics, Inc.
Oncodrone BV
Osteologix Holdings Plc
R-Pharm
Sigma-Tau S.p.A.
Terpenoid Therapeutics, Inc.
Thar Pharmaceuticals, Inc.
Bone Metastasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AB-25E9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADM-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALX-0141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-3701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit EGFR for Bone Metastasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ki-26894 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MIV-711 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NBS-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OCD-155 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radium Ra 223 dichloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
roneparstat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RPH-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RSF-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RSF-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit GGDP for Cancer and Bone Metastasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TPH-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vicrostatin - Drug Profile
Product Description
Mechanism of Action

R&D Progress

zoledronic acid - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Bone Metastasis - Recent Pipeline Updates

Bone Metastasis - Dormant Projects

Bone Metastasis - Discontinued Products

Bone Metastasis - Product Development Milestones

Featured News & Press Releases

May 23, 2014: Daiichi Sankyo Receives Approval in Japan for Additional Indication Related to RANMARK for Treatment of Giant Cell Tumor of Bone

Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders

Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics

Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo

Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway

May 30, 2013: Algeta Announces First Sale Of Xofigo In US

Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium

Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride

Oct 23, 2012: Amgen's Xgeva Obtains Approval From NICE For Eligibility To NHS Funding

Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress

Appendix

Methodology

Coverage

Secondary Research
Number of Products under Development for Bone Metastasis, H2 2015
Number of Products under Development for Bone Metastasis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Bone Metastasis - Pipeline by Ablynx NV, H2 2015
Bone Metastasis - Pipeline by Aegera Therapeutics Inc., H2 2015
Bone Metastasis - Pipeline by Alethia Biotherapeutics Inc., H2 2015
Bone Metastasis - Pipeline by Amgen Inc., H2 2015
Bone Metastasis - Pipeline by Amura Holdings Limited, H2 2015
Bone Metastasis - Pipeline by Bayer AG, H2 2015
Bone Metastasis - Pipeline by ChemoCentryx, Inc., H2 2015
Bone Metastasis - Pipeline by Debiopharm International S.A., H2 2015
Bone Metastasis - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
Bone Metastasis - Pipeline by Digna Biotech, S.L., H2 2015
Bone Metastasis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Bone Metastasis - Pipeline by Medivir AB, H2 2015
Bone Metastasis - Pipeline by Merrion Pharmaceuticals Plc, H2 2015
Bone Metastasis - Pipeline by Oncobiologics, Inc., H2 2015
Bone Metastasis - Pipeline by Oncodrone BV , H2 2015
Bone Metastasis - Pipeline by Osteologix Holdings Plc, H2 2015
Bone Metastasis - Pipeline by R-Pharm, H2 2015
Bone Metastasis - Pipeline by Sigma-Tau S.p.A., H2 2015
Bone Metastasis - Pipeline by Terpenoid Therapeutics, Inc., H2 2015
Bone Metastasis - Pipeline by Thar Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Bone Metastasis Therapeutics - Recent Pipeline Updates, H2 2015
Bone Metastasis - Dormant Projects, H2 2015
Bone Metastasis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Bone Metastasis, H2 2015
Number of Products under Development for Bone Metastasis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3448656/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Bone Metastasis - Pipeline Review, H2 2015
Web Address: http://www.researchandmarkets.com/reports/3448656/
Office Code: SCD27FCO

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: 
Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp